Bax Predicts Outcome in Gastric Cancer Patients Treated with 5-fluorouracil, Leucovorin, and Oxaliplatin Palliative Chemotherapy

被引:33
作者
Jeong, Seong Hyun [1 ]
Han, Jae Ho [2 ]
Kim, Jang Hee [2 ]
Ahn, Mi Sun [1 ]
Hwang, Yoon Ho [1 ]
Lee, Hyun Woo [1 ]
Kang, Seok Yun [1 ]
Park, Joon Seong [1 ]
Choi, Jin-Hyuk [1 ]
Lee, Kwang Jae [3 ]
Sheen, Seung Soo [4 ]
Lim, Ho-Yeong [5 ]
机构
[1] Ajou Univ, Sch Med, Dept Hematol Oncol, Suwon 443721, South Korea
[2] Ajou Univ, Sch Med, Dept Pathol, Suwon 443721, South Korea
[3] Ajou Univ, Sch Med, Dept Gastroenterol, Suwon 443721, South Korea
[4] Ajou Univ, Sch Med, Sect Clin Epidemiol & Biostat, Clin Trial Ctr, Suwon 443721, South Korea
[5] Sungkyunkwan Univ, Sch Med, Div Hematol Oncol, Dept Med,Samsung Med Ctr, Suwon, South Korea
关键词
Gastric cancer; Bax; Chemotherapy; Prognosis; MESSENGER-RNA LEVELS; CELL LUNG-CANCER; THYMIDYLATE SYNTHASE; ADJUVANT CHEMOTHERAPY; 1ST-LINE CHEMOTHERAPY; TUMOR RESPONSE; LOW EXPRESSION; FOLINIC ACID; PHASE-II; ERCC1;
D O I
10.1007/s10620-010-1280-8
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Platinum and 5-fluorouracil (5-FU)-based regimens have been used the most frequently in palliative chemotherapy for gastric cancer. The present study evaluated the prognostic significance of Bax, excision repair cross-complementation group 1 (ERCC1), and thymidylate synthase (TS) in advanced gastric cancer patients treated with 5-FU, leucovorin, and oxaliplatin (FOLFOX) palliative chemotherapy. Methods Seventy-two patients with metastatic or recurrent gastric cancer were treated with FOLFOX regimen. Pretreatment tumor biopsy specimens were analyzed for Bax, ERCC1, and TS expression by immunohistochemistry. Results High expression of Bax, ERCC1, and TS was observed in 31 (43%), 33 (46%), and 35 (49%) patients, respectively. The median overall survival (OS) of patients was 12 months. Low expression of Bax was associated with poor OS (median, 9 months vs. 18 months; 2-year, 10% vs. 48%; p = 0.0005) in univariate analysis, while expression of ERCC1 and TS was not correlated with patient outcome. In multivariate analysis, low expression of Bax was a significant independent predictor of poor OS (p = 0.028). Low expression of Bax was significantly associated with poor survival of patients with metastatic or recurrent gastric cancer treated with FOLFOX chemotherapy. Conclusions Immunohistochemical staining for Bax with pretreatment biopsy specimen may be useful in selecting FOLFOX regimen as a treatment option for advanced gastric cancer patients.
引用
收藏
页码:131 / 138
页数:8
相关论文
共 34 条
[1]   Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin:: A study of the arbeitsgemeinschaft internistische onkologie [J].
Al-Batran, Salah-Eddin ;
Hartmann, Joerg Thomas ;
Probst, Stephan ;
Schmalenberg, Harald ;
Hollerbach, Stephan ;
Hofheinz, Ralf ;
Rethwisch, Volker ;
Seipelt, Gernot ;
Homann, Nils ;
Wilhelm, Gerhard ;
Schuch, Gunter ;
Stoehlmacher, Jan ;
Derigs, Hans Guenter ;
Hegewisch-Becker, Susanna ;
Grossmann, Johannes ;
Pauligk, Claudia ;
Atmaca, Akin ;
Bokemeyer, Carsten ;
Knuth, Alexander ;
Jaeger, Elke .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) :1435-1442
[2]  
Boku N, 1998, CLIN CANCER RES, V4, P1469
[3]   Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data [J].
Chou, I ;
Norman, AR ;
Cunningham, D ;
Waters, JS ;
Oates, J ;
Ross, PJ .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2395-2403
[4]  
COX DR, 1972, J R STAT SOC B, V34, P187
[5]   Capecitabine and oxaliplatin for advanced esophagogastric cancer [J].
Cunningham, David ;
Starling, Naureen ;
Rao, Sheela ;
Iveson, Timothy ;
Nicolson, Marianne ;
Coxon, Fareeda ;
Middleton, Gary ;
Daniel, Francis ;
Oates, Jacqueline ;
Norman, Andrew Richard .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (01) :36-46
[6]   A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients [J].
De Vita, F ;
Orditura, M ;
Matano, E ;
Bianco, R ;
Carlomagno, C ;
Infusino, S ;
Damiano, V ;
Simeone, E ;
Diadema, MR ;
Lieto, E ;
Castellano, P ;
Pepe, S ;
De Placido, S ;
Galizia, G ;
Di Martino, N ;
Ciardiello, F ;
Catalano, G ;
Bianco, AR .
BRITISH JOURNAL OF CANCER, 2005, 92 (09) :1644-1649
[7]   Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy [J].
Fulda, S. ;
Debatin, K. -M .
ONCOGENE, 2006, 25 (34) :4798-4811
[8]   ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer [J].
Huang, Zhao-Hui ;
Hua, Dong ;
Du, Xiang ;
Li, Li-Hua ;
Mao, Yong ;
Liu, Zhi-Hui ;
Song, Ming-Xu ;
Zhou, Xi-Ke .
WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (41) :6401-6407
[9]   Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients [J].
Ichikawa, W. ;
Sasaki, Y. .
ANNALS OF ONCOLOGY, 2006, 17 (11) :1665-1672
[10]  
Kang SY, 2006, NEOPLASMA, V53, P450